1. Jivi, manufactured by Bayer, is a long-acting treatment for hemophilia A, a rare, genetic bleeding disorder. It is an injection for patients 12 years or older.
2. Imbruvica plus Rituxan, is a combination drug for the treatment of adult patients with Waldenstrom macroglobulinemia, a rare and incurable type of Non-Hodgkin lymphoma.
3. Merck received FDA approval for Delstrigo, a once-daily fixed-dose combination tablet of doravirine, lamivudine and tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults.
4. Pifeltro is a non-nucleoside reverse transcriptase inhibitor, which is to be used in combination with other antiretroviral medicines for the treatment of HIV-1 infection in adults.
More articles on supply chain:
Hawaii blood bank makes urgent call for donors in wake of tropical storm
Infographic: OR Supply Chain- Let’s Talk about Change
A steroid to treat eye pain, a nontraditional OCD treatment & more: 4 latest FDA approvals
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
